PLUR Quote, Financials, Valuation and Earnings

IR-Med has a net margin of -1804.3% compared to Pluri's net margin of --. Pluri's return on equity of -438.78% beat IR-Med's return on equity of --.

Pluri has a consensus price target of --, signalling upside risk potential of 619.1%. On the other hand IR-Med has an analysts' consensus of -- which suggests that it could fall by --. Given that Pluri has higher upside potential than IR-Med, analysts believe Pluri is more attractive than IR-Med.

Pluri has a beta of 1.642, which suggesting that the stock is 64.245% more volatile than S&P 500. In comparison IR-Med has a beta of 1.789, suggesting its more volatile than the S&P 500 by 78.878%.

Pluri has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IR-Med offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pluri pays -- of its earnings as a dividend. IR-Med pays out -- of its earnings as a dividend.

Pluri quarterly revenues are $326K, which are larger than IR-Med quarterly revenues of --. Pluri's net income of -$5.9M is lower than IR-Med's net income of -$598K. Notably, Pluri's price-to-earnings ratio is -- while IR-Med's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pluri is 39.53x versus -- for IR-Med. Usually stocks with elevated PS ratios are considered overvalued.

InspireMD has a net margin of -1804.3% compared to Pluri's net margin of -435.91%. Pluri's return on equity of -438.78% beat InspireMD's return on equity of -68.55%.

Pluri has a consensus price target of --, signalling upside risk potential of 619.1%. On the other hand InspireMD has an analysts' consensus of -- which suggests that it could grow by 66.08%. Given that Pluri has higher upside potential than InspireMD, analysts believe Pluri is more attractive than InspireMD.

Pluri has a beta of 1.642, which suggesting that the stock is 64.245% more volatile than S&P 500. In comparison InspireMD has a beta of 0.985, suggesting its less volatile than the S&P 500 by 1.474%.

Pluri has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InspireMD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pluri pays -- of its earnings as a dividend. InspireMD pays out -- of its earnings as a dividend.

Pluri quarterly revenues are $326K, which are smaller than InspireMD quarterly revenues of $1.8M. Pluri's net income of -$5.9M is higher than InspireMD's net income of -$7.9M. Notably, Pluri's price-to-earnings ratio is -- while InspireMD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pluri is 39.53x versus 15.95x for InspireMD. Usually stocks with elevated PS ratios are considered overvalued.

BiomX has a net margin of -1804.3% compared to Pluri's net margin of --. Pluri's return on equity of -438.78% beat BiomX's return on equity of --.

Pluri has a consensus price target of --, signalling upside risk potential of 619.1%. On the other hand BiomX has an analysts' consensus of -- which suggests that it could grow by 1187.48%. Given that BiomX has higher upside potential than Pluri, analysts believe BiomX is more attractive than Pluri.

Pluri has a beta of 1.642, which suggesting that the stock is 64.245% more volatile than S&P 500. In comparison BiomX has a beta of 1.314, suggesting its more volatile than the S&P 500 by 31.404%.

Pluri has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pluri pays -- of its earnings as a dividend. BiomX pays out -- of its earnings as a dividend.

Pluri quarterly revenues are $326K, which are larger than BiomX quarterly revenues of --. Pluri's net income of -$5.9M is lower than BiomX's net income of $9.6M. Notably, Pluri's price-to-earnings ratio is -- while BiomX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pluri is 39.53x versus -- for BiomX. Usually stocks with elevated PS ratios are considered overvalued.

Raphael Pharmaceutical has a net margin of -1804.3% compared to Pluri's net margin of --. Pluri's return on equity of -438.78% beat Raphael Pharmaceutical's return on equity of --.

Pluri has a consensus price target of --, signalling upside risk potential of 619.1%. On the other hand Raphael Pharmaceutical has an analysts' consensus of -- which suggests that it could fall by --. Given that Pluri has higher upside potential than Raphael Pharmaceutical, analysts believe Pluri is more attractive than Raphael Pharmaceutical.

Pluri has a beta of 1.642, which suggesting that the stock is 64.245% more volatile than S&P 500. In comparison Raphael Pharmaceutical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pluri has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Raphael Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pluri pays -- of its earnings as a dividend. Raphael Pharmaceutical pays out -- of its earnings as a dividend.

Pluri quarterly revenues are $326K, which are larger than Raphael Pharmaceutical quarterly revenues of --. Pluri's net income of -$5.9M is lower than Raphael Pharmaceutical's net income of -$326K. Notably, Pluri's price-to-earnings ratio is -- while Raphael Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pluri is 39.53x versus -- for Raphael Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.